Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 5.35 is 132% above its 5-year average of 2.31, near the high end of its 5-year range (0.15–5.78).
As of the fiscal period ended Tuesday, June 30, 2026. 26.89% above its 12-month average of 4.21.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.35.
CURRENT RATIO
5.35
CURRENT RATIO AVG TTM
4.21
CURRENT RATIO AVG 3Y
2.24
CURRENT RATIO AVG 5Y
2.31
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+26.89%
CURRENT VS 3Y AVG
+138.43%
CURRENT VS 5Y AVG
+131.75%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+42.60%
vs the sector median at left
TriSalus Life Sciences, Inc.
Market Cap
$271.54M
Current Ratio
5.35
TTM Avg
4.21
3Y Avg
2.24
5Y Avg
2.31
Market Cap
$271.00M
Current Ratio
4.85
TTM Avg
6.69
3Y Avg
6.56
5Y Avg
6.64
Market Cap
$272.44M
Current Ratio
9.24
TTM Avg
7.84
3Y Avg
8.19
5Y Avg
10.90
Market Cap
$270.31M
Current Ratio
1.61
TTM Avg
3.39
3Y Avg
4.35
5Y Avg
5.01
Market Cap
$270.26M
Current Ratio
9.22
TTM Avg
6.22
3Y Avg
4.84
5Y Avg
4.06
Market Cap
$266.63M
Current Ratio
2.90
TTM Avg
4.46
3Y Avg
4.43
5Y Avg
4.81
Market Cap
$265.39M
Current Ratio
15.82
TTM Avg
24.04
3Y Avg
14.70
5Y Avg
12.06
Market Cap
$264.94M
Current Ratio
4.50
TTM Avg
8.35
3Y Avg
6.79
5Y Avg
6.91
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TriSalus Life Sciences, Inc. (TLSI) | $271.54M | 5.35 | 4.21 | 2.24 | 2.31 |
| Fate Therapeutics, Inc. (FATE)vs › | $271.00M | 4.85 | 6.69 | 6.56 | 6.64 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $272.44M | 9.24 | 7.84 | 8.19 | 10.90 |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.31M | 1.61 | 3.39 | 4.35 | 5.01 |
| SAB Biotherapeutics, Inc. (SABS)vs › | $270.26M | 9.22 | 6.22 | 4.84 | 4.06 |
| Scribe Therapeutics Inc. (SCTX)vs › | $270.23M | N/A | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $266.63M | 2.90 | 4.46 | 4.43 | 4.81 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $265.39M | 15.82 | 24.04 | 14.70 | 12.06 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.94M | 4.50 | 8.35 | 6.79 | 6.91 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.10M | 16.00 | 13.11 | 8.33 | 7.81 |
Current Ratio
5.35
Quick Ratio
4.97
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 5.35 |
| 2026-03-31 | 5.78 |
| 2025-12-31 | 2.80 |
| 2025-09-30 | 3.05 |
| 2025-06-30 | 4.08 |
| 2025-03-31 | 2.14 |
| 2024-12-31 | 2.02 |
| 2024-09-30 | 2.40 |
| 2024-06-30 | 2.33 |
| 2024-03-31 | 0.92 |
| 2023-12-31 | 1.42 |
| 2023-09-30 | 3.12 |
| 2023-06-30 | 0.38 |
| 2023-03-31 | 0.68 |
| 2022-12-31 | 0.53 |
| 2022-09-30 | 1.30 |
| 2022-06-30 | 0.15 |
| 2022-03-31 | 0.17 |
| 2021-12-31 | 5.51 |
| 2021-09-30 | 1.01 |
| 2021-06-30 | 3.30 |
| 2021-03-31 | 10.98 |
| 2020-12-31 | 0.11 |
| 2020-09-30 | 0.57 |
